Market Access How new PBM transparency rules will alter drug pricing The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.
Sales & Marketing Is pure play pharma's new pharmakon? The shift in commercial teams has been happening for some time. This is not new news. I have felt it many times over, like many of us who have worked in the industry for years.
News FDA renews criticism of trial sponsors over transparency The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative.
Patients Patient centricity in psychiatric management: Bipolar I Discover what clinicians can do to foster more patient-centred psychiatric care in a Q&A with neuropsychiatric physician assistant Rebecca Barbee.
Digital Harnessing AI to make Medicare more efficient, fair, and pat... As part of “WISeR” requirements, CMS selected tech vendors to implement enhanced technological models to scrutinise claims involving those on Medicare
Digital AI is reshaping drug discovery - Now it must prove it can be... As innovation pushes the boundaries of speed and scale, a question remains: can we use transparency as a way to prove safety and build public trust?
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.